Showing results (281-290 of 291) with videos related to
Sort By:
Pageof 30
Frontiers in Immunology|November 30, 2023
Liquid Biopsy in Organ Damage: small extracellular vesicle chip-based assessment of polytraumaBingduo Wang, Aliona Wöhler, Johannes Greven, et al.Haematologica|April 3, 2016
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapyMarie-Luise Hütter-Krönke, Axel Benner, Konstanze Döhner, et al.BMC Cancer|May 11, 2021
No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in GermanyRoman Rüdiger, Franziska Geiser, Manuel Ritter, et al.Journal of Clinical Medicine|July 13, 2024
Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local Treatment with US-Guided High-Intensity Focused Ultrasound in Combination with Palliative Chemotherapy in Inoperable Pancreatic CancerMilka Marinova, David-Alexis Khouri, Jim Küppers, et al.BMC Cancer|November 1, 2019
A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer CenterMarie K Budde, Walther Kuhn, Mignon-Denise Keyver-Paik, et al.Blood|December 14, 2011
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pKai Neben, Henk M Lokhorst, Anna Jauch, et al.BMC Cancer|April 27, 2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myelomaMarc-Andrea Baertsch, Jana Schlenzka, Elias K Mai, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative GroupStefan Gröschel, Richard F Schlenk, Jan Engelmann, et al.Haematologica|September 3, 2013
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trialChristof Scheid, Pieter Sonneveld, Ingo G H Schmidt-Wolf, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trialPieter Sonneveld, Ingo G H Schmidt-Wolf, Bronno van der Holt, et al.Pageof 30